Form 4 for ZBIO Zenas BioPharma, Inc.
Accepted 2024-11-20 00:00:00 ET · period of report 2024-11-18 · accession 0001104659-24-121081 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-11-20 | 2024-11-18+ | ZBIO | MOULDER LEON O JR | CEO, Dir | P - Purchase | $14.89 | +10.0K | 171.2K | +6% | +$148.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-18 | P | A | 7,500 | $15.00 | 168,655 | D | — | — | (F1) The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $14.81 to $15.32, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |
| 2 | Common | Common Stock | 2024-11-19 | P | A | 2,500 | $14.57 | 171,155 | D | — | — | (F2) The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $14.50 to $14.62, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |